Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Vuno Inc. (338220:KRX), powered by AI.
Vuno Inc. is currently trading at ₩8,750. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Vuno Inc. on Alpha Lenz.
Vuno Inc.'s P/E ratio is -21.2.
“Vuno Inc. trades at a P/E of -21.2 (undervalued) with modest ROE of -17.3%. 3Y revenue CAGR of 61.5% highlights clear growth momentum.”
Ask for details →Vuno Inc. is a South Korea-based company specializing in artificial intelligence (AI) solutions within the healthcare sector. Its primary function is to develop innovative AI-driven technologies that assist medical professionals in diagnosing and managing patient conditions more effectively. Vuno's software applications harness the power of deep learning algorithms to analyze vast amounts of medical data, including imaging and pathology, with high precision and speed. The company’s prominent solutions extend across various medical fields such as radiology, cardiology, and genomics, enhancing clinical outcomes and efficiency. Known for its cutting-edge AI products like VUNO Med, Vuno Inc. plays a pivotal role in the digital transformation of healthcare, contributing to advancements in early disease detection and personalized medicine. In the global market, the company’s technologies are regarded as enhancing accuracy in diagnostic processes, ultimately improving patient care. Positioned as a leader in AI healthcare innovation, Vuno Inc. continuously seeks to expand its influence through partnerships and collaborations with medical institutions, contributing significantly to the evolution of health tech industry standards.
“Vuno Inc. trades at a P/E of -21.2 (undervalued) with modest ROE of -17.3%. 3Y revenue CAGR of 61.5% highlights clear growth momentum.”
Ask for details →Vuno Inc. (ticker: 338220) is a company listed on KRX in the Healthcare sector (Health Information Services). It has approximately 142 employees. Market cap is $122.5B.
The current price is ₩8,750 with a P/E ratio of -21.2x and P/B of 3.39x.
ROE is -17.30% and operating margin is -14.16%. Annual revenue is $34.8B.